div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: · 1 gátlásban Új szerek az anti-IL-6 gátlásban Agent REGN88 sarilumab CNTo-136 sirukumab CNT0-328 siltuximab CDP-6038 olokizumab BMS-94S429 formerly ALD518 Agent ABX-lL8 src=https:reader036fdocumentocomreader036viewer20220814025f0c0d7d7e708231d433836chtml5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: · 1 gátlásban Új szerek az anti-IL-6 gátlásban Agent REGN88 sarilumab CNTo-136 sirukumab CNT0-328 siltuximab CDP-6038 olokizumab BMS-94S429 formerly ALD518 Agent ABX-lL8 src=https:reader036fdocumentocomreader036viewer20220814025f0c0d7d7e708231d433836chtml5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: · 1 gátlásban Új szerek az anti-IL-6 gátlásban Agent REGN88 sarilumab CNTo-136 sirukumab CNT0-328 siltuximab CDP-6038 olokizumab BMS-94S429 formerly ALD518 Agent ABX-lL8 src=https:reader036fdocumentocomreader036viewer20220814025f0c0d7d7e708231d433836chtml5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: · 1 gátlásban Új szerek az anti-IL-6 gátlásban Agent REGN88 sarilumab CNTo-136 sirukumab CNT0-328 siltuximab CDP-6038 olokizumab BMS-94S429 formerly ALD518 Agent ABX-lL8 src=https:reader036fdocumentocomreader036viewer20220814025f0c0d7d7e708231d433836chtml5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: · 1 gátlásban Új szerek az anti-IL-6 gátlásban Agent REGN88 sarilumab CNTo-136 sirukumab CNT0-328 siltuximab CDP-6038 olokizumab BMS-94S429 formerly ALD518 Agent ABX-lL8...